Disease awareness or subtle product placement?

• Verfasst von: Mechler, Konstantin [VerfasserIn]
• Verfasst von: Rausch, Juliane [VerfasserIn]
• Verfasst von: Mountford, William K. [VerfasserIn]
• Verfasst von: Ries, Markus [VerfasserIn]
• Titel: Disease awareness or subtle product placement?
• Titelzusatz: Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis
• Verf.angabe: Konstantin Mechler, Juliane Rausch, William K. Mountford and Markus Ries
• E-Jahr: 2020
• Jahr: 14 March 2020
• Fussnoten: Gesehen am 30.03.2020
• Titel Quelle: Enthalten in: BMC medical ethics
• Ort Quelle: London : BioMed Central, 2000
• Jahr Quelle: 2020
• Band/Heft Quelle: 21(2020) Artikel-Nummer 20, 8 Seiten
• ISSN Quelle: 1472-6939
• DOI: doi:10.1186/s12910-020-0463-x
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1693510634
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Approximately 7% of the general population is affected by an orphan disease, which, in the United States, is defined as affecting fewer than 1 in 1500 people. Disease awareness is often low and time-to-diagnosis delayed. Different legislations worldwide have created incentives for pharmaceutical companies to develop drugs for orphan diseases. A journalistic article in Bloomberg Businessweek has claimed that pharmaceutical companies have tried marketing orphan drugs by placing a specific disease into the popular television series “House, M.D.” which features diagnostic journeys and was produced between 2004 and 2012. This study aimed to describe the presentation of orphan diseases in the television series “House, M.D.”, to test in an exploratory fashion the hypothesis that treatable orphan conditions are overrepresented in “House, M.D.” and to discuss whether such marketing practices may or may not be ethical.